Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Dermata Therapeutics ( (DRMA) ) just unveiled an update.
On September 10, 2025, Dermata Therapeutics announced a strategic shift to focus on over-the-counter dermatology products, starting with a weekly acne kit using their Spongilla technology. This pivot includes withdrawing their investigational new drug application for XYNGARI™ with the FDA, indicating a significant change in their market strategy.
The most recent analyst rating on (DRMA) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Dermata Therapeutics stock, see the DRMA Stock Forecast page.
Spark’s Take on DRMA Stock
According to Spark, TipRanks’ AI Analyst, DRMA is a Underperform.
Dermata Therapeutics’ stock is primarily impacted by its financial health, characterized by significant operating losses and reliance on external financing. Technical analysis indicates a bearish trend with potential overselling, while valuation remains difficult to assess due to negative earnings. These factors contribute to a low overall score.
To see Spark’s full report on DRMA stock, click here.
More about Dermata Therapeutics
Dermata Therapeutics operates in the pharmaceutical industry, focusing on dermatology products. The company is known for its innovative Spongilla technology and aims to provide over-the-counter solutions for skin conditions.
Average Trading Volume: 20,479
Technical Sentiment Signal: Sell
Current Market Cap: $3.58M
See more insights into DRMA stock on TipRanks’ Stock Analysis page.